PriceTargets.com logo

NASDAQ:KROS - Keros Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $85.00
  • Forecasted Upside: 177.96 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$30.58 As of 09/23/2021 03:04 PM ET
▼ -0.22 (-0.71%)

This chart shows the closing price for KROS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Keros Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KROS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KROS

Analyst Price Target is $85.00
▲ +177.96% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Keros Therapeutics in the last 3 months. The average price target is $85.00, with a high forecast of $100.00 and a low forecast of $70.00. The average price target represents a 177.96% upside from the last price of $30.58.

This chart shows the closing price for KROS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Keros Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2021HC WainwrightReiterated RatingBuy$100.00Medium
8/6/2021Piper SandlerLower Price TargetOverweight$95.00 ➝ $90.00Low
6/27/2021SVB LeerinkReiterated RatingBuyLow
6/23/2021Jefferies Financial GroupReiterated RatingBuy$70.00High
12/8/2020HC WainwrightBoost Price TargetBuy$50.00 ➝ $100.00High
12/8/2020SVB LeerinkBoost Price TargetOutperform$42.00 ➝ $80.00High
12/8/2020Piper SandlerBoost Price TargetOverweight$75.00 ➝ $95.00High
11/18/2020Piper SandlerBoost Price TargetOverweight$55.00 ➝ $75.00Low
9/13/2020Piper SandlerBoost Price TargetOverweight$45.00 ➝ $55.00Medium
5/27/2020Piper SandlerBoost Price TargetOverweight$35.00 ➝ $45.00High
5/4/2020HC WainwrightInitiated CoverageBuy$50.00Medium
5/4/2020SVB LeerinkInitiated CoverageOutperform$42.00Medium
5/4/2020Jefferies Financial GroupInitiated CoverageBuy$37.00Medium
5/3/2020Piper SandlerInitiated CoverageOverweight$35.00Medium
(Data available from 9/23/2016 forward)

News Sentiment Rating

-0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/25/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/25/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Keros Therapeutics logo
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $30.58
Low: $30.07
High: $30.90

50 Day Range

MA: $34.29
Low: $29.27
High: $40.75

52 Week Range

Now: $30.58
Low: $28.50
High: $88.80

Volume

1,664 shs

Average Volume

127,030 shs

Market Capitalization

$713.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Keros Therapeutics?

The following Wall Street analysts have issued stock ratings on Keros Therapeutics in the last twelve months: HC Wainwright, Jefferies Financial Group Inc., Piper Sandler, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for KROS.

What is the current price target for Keros Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Keros Therapeutics in the last year. Their average twelve-month price target is $85.00, suggesting a possible upside of 178.0%. HC Wainwright has the highest price target set, predicting KROS will reach $100.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $70.00 for Keros Therapeutics in the next year.
View the latest price targets for KROS.

What is the current consensus analyst rating for Keros Therapeutics?

Keros Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KROS will outperform the market and that investors should add to their positions of Keros Therapeutics.
View the latest ratings for KROS.

How do I contact Keros Therapeutics' investor relations team?

Keros Therapeutics' physical mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The official website for Keros Therapeutics is www.kerostx.com.